查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1945489

2026年全球肝癌诊断市场报告

Liver Cancer Diagnostics Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，肝癌诊断市场成长显着，预计将从2025年的103.2亿美元成长到2026年的110.7亿美元，复合年增长率为7.3%。过去几年的增长可归因于慢性肝病盛行率的上升、肝细胞癌发生率的增加、医院诊断基础设施的扩建、早期癌症筛检意识提升以及影像诊断和病理技术的进步。

预计未来几年肝癌诊断市场规模将维持强劲成长，2030年将达到147.5亿美元，复合年增长率（CAGR）为7.4%。预测期内的成长可归因于精准肿瘤诊断技术的日益普及、对非侵入性诊断方法需求的不断增长、分子检测能力的提升、肿瘤研究投入的增加以及人工智慧辅助诊断平台的广泛应用。预测期内的关键趋势包括：先进分子诊断检测技术的日益普及、基于影像的早期检测工具的广泛应用、基于生物标誌物的筛检方法的日益整合、个性化癌症诊断的扩展以及对早期癌症检测的日益重视。

预计肝癌发生率的上升将推动肝癌诊断市场的成长。肝癌的特征是肝细胞不受控制地增殖，并会带来严重的健康风险。肝癌诊断测试在确定原发性肝癌确诊后癌细胞在肝臟内或周围的扩散程度方面发挥着至关重要的作用。根据美国癌症协会 (ACS) 的报告，女性肝癌和肝内胆管癌的新病例数正在上升，预计到 2023 年，美国将达到 13,230 例。预计 2023 年美国新增肝癌病例总数将达 41,210 例，预计死亡人数将达 29,380 人。这凸显了在肝癌发生率不断上升的情况下，肝癌诊断的迫切性。

肝癌诊断市场的主要企业正在开发先进的基于生物标记的检测方法和演算法，以提高诊断准确性并促进早期发现。基于生物标记的检测方法和演算法是利用特定生物标记来识别疾病的诊断工具，能够提供更精准、更有效率的诊断能力。例如，2023年11月，美国生物技术公司罗氏诊断推出了Elexis PIVKA-II检测和Elexis GAAD演算法。 Elexis PIVKA-II检测能够辨识PIVKA-II水平升高，PIVKA-II是一种与肝细胞癌（HCC）相关的生物标记物，从而提高高风险患者肝癌的早期检出率。同时，Elexis GAAD演算法结合了包括PIVKA-II和AFP在内的多种诊断标记物，旨在提高诊断准确性并简化肝癌检测的决策过程。

目录

第一章执行摘要

第二章 市场特征

  • 市场定义和范围
  • 市场区隔
  • 主要产品和服务概述
  • 全球肝癌诊断市场：吸引力评分及分析
  • 成长潜力分析、竞争评估、策略契合度评估、风险状况评估

第三章 市场供应链分析

  • 供应链与生态系概述
  • 主要原料、资源和供应商清单
  • 主要经销商和通路合作伙伴名单
  • 主要最终用户列表

第四章 全球市场趋势与策略

  • 关键技术和未来趋势
    • 生物技术、基因组学和精准医学
    • 人工智慧（AI）和自主人工智慧
    • 数位化、云端运算、巨量资料、网路安全
    • 工业4.0和智慧製造
    • 物联网、智慧基础设施和互联生态系统
  • 主要趋势
    • 先进分子诊断测试的普及率不断提高
    • 更多地使用基于成像的早期检测工具
    • 生物标记筛检方法整合的进展
    • 扩大个人化癌症诊断
    • 人们越来越重视癌症早期检测

第五章 终端用户产业市场分析

  • 医院
  • 诊断检查室
  • 学术研究机构
  • 製药公司
  • CRO（受託研究机构）

第六章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税的影响、关税战和贸易保护主义对供应链的影响，以及新冠疫情对市场的影响

第七章 全球策略分析架构、目前市场规模、市场对比及成长率分析

  • 全球肝癌诊断市场：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素与限制因素）
  • 全球肝癌诊断市场规模、对比及成长率分析
  • 全球肝癌诊断市场表现：规模与成长，2020-2025年
  • 全球肝癌诊断市场预测：规模与成长，2025-2030年，2035年预测

第八章 全球潜在市场规模（TAM）

第九章 市场细分

  • 按类型
  • 肝细胞癌、胆管癌、肝母细胞瘤
  • 透过筛检
  • 检查室检查、影像学检查、切片检查和其他筛检
  • 透过技术
  • 萤光原位杂合反应（FISH）、免疫组织化学（IHC）及其他技术
  • 按最终用途
  • 医院及诊断检查室、学术研究机构
  • 按类型细分：肝细胞癌
  • 早期肝细胞癌，晚期肝细胞癌
  • 按类型细分：胆管癌
  • 肝内胆管癌，肝外胆管癌
  • 依类型细分：肝母细胞瘤
  • 纯型肝母细胞瘤，混合型肝母细胞瘤

第十章 区域与国家分析

  • 全球肝癌诊断市场：依地区、绩效及预测划分，2020-2025年、2025-2030年预测、2035年预测
  • 全球肝癌诊断市场：依国家、绩效及预测划分，2020-2025年、2025-2030年预测、2035年预测

第十一章 亚太市场

第十二章：中国市场

第十三章 印度市场

第十四章 日本市场

第十五章：澳洲市场

第十六章 印尼市场

第十七章 韩国市场

第十八章 台湾市场

第十九章 东南亚市场

第二十章：西欧市场

第21章英国市场

第22章 德国市场

第23章：法国市场

第24章：义大利市场

第25章：西班牙市场

第26章 东欧市场

第27章：俄罗斯市场

第28章 北美市场

第29章：美国市场

第30章：加拿大市场

第31章 南美洲市场

第32章：巴西市场

第33章 中东市场

第34章：非洲市场

第35章 市场监理与投资环境

第36章：竞争格局与公司概况

  • 肝癌诊断市场：竞争格局及市场占有率（2024年）
  • 肝癌诊断市场：公司估值矩阵
  • 肝癌诊断市场：公司概况
    • Abbott Laboratories
    • F Hoffmann La Roche Ltd
    • Qiagen NV
    • Thermo Fisher Scientific Inc
    • Siemens Healthineers

第37章：其他领先和创新企业

  • Illumina Inc, Koninklijke Philips NV, Epigenomics AG, Digna Biotech SL, Biocept Inc, Danaher Corporation, Foundation Medicine Inc, Agilent Technologies Inc, Genemed Biotechnologies Inc, Merck KGaA, Fujifilm Medical Systems USA Inc, GE Healthcare, Advanced Cell Diagnostics Inc, Oxford Gene Technology, Leica Biosystems Nussloch GmbH

第38章 全球市场竞争基准分析与仪錶板

第39章 重大併购

第四十章：高潜力市场国家、细分市场与策略

  • 2030年肝癌诊断市场：提供新机会的国家
  • 2030年肝癌诊断市场：蕴藏新机会的细分市场
  • 2030年肝癌诊断市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第41章附录

简介目录
Product Code: ME4MLCDA01_G26Q1

Liver cancer diagnostics encompass a range of techniques utilized for the identification and assessment of liver cancer, a malignancy originating in the liver. These methods play a crucial role in the early detection and diagnosis of liver cancer, utilizing both imaging and molecular testing.

Hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and other related forms constitute the primary types of cancer addressed in liver cancer diagnostics. Hepatocellular carcinoma (HCC) specifically pertains to the predominant liver cancer affecting individuals with cirrhosis and preexisting chronic liver disease. The screening process involves various approaches such as laboratory testing, imaging, endoscopy, biopsy, and others. Diverse technologies, including fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH), immunohistochemical (IHC), among others, are employed across different end uses, including hospitals and diagnostic laboratories, academic and research institutes, and pharmaceutical and CRO laboratories.

Tariffs are impacting the liver cancer diagnostics market by increasing costs of imported imaging systems, laboratory analyzers, reagents, molecular testing kits, and diagnostic consumables used across hospitals and diagnostic laboratories. North America and Europe are most affected due to reliance on advanced imported diagnostic equipment, while Asia-Pacific faces cost pressures on reagents and imaging device imports. These tariffs are raising diagnostic procedure costs and slowing equipment upgrades. However, they are also encouraging domestic manufacturing of diagnostic kits, regional reagent production, and localized development of imaging and molecular diagnostic technologies.

The liver cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides liver cancer diagnostics market statistics, including liver cancer diagnostics industry global market size, regional shares, competitors with a liver cancer diagnostics market share, detailed liver cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the liver cancer diagnostics industry. This liver cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liver cancer diagnostics market size has grown strongly in recent years. It will grow from $10.32 billion in 2025 to $11.07 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing prevalence of chronic liver diseases, rising incidence of hepatocellular carcinoma, expansion of hospital diagnostic infrastructure, growing awareness of early cancer screening, advancements in imaging and pathology techniques.

The liver cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $14.75 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing adoption of precision oncology diagnostics, rising demand for non-invasive diagnostic methods, expansion of molecular testing capabilities, growing investments in oncology research, increasing use of ai-assisted diagnostic platforms. Major trends in the forecast period include increasing adoption of advanced molecular diagnostic tests, rising use of imaging-based early detection tools, growing integration of biomarker-based screening methods, expansion of personalized oncology diagnostics, enhanced focus on early-stage cancer detection.

The anticipated rise in the prevalence of liver cancer is set to drive the growth of the liver cancer diagnostics market. Liver cancer, characterized by the uncontrolled growth of liver cells, poses a severe health risk. Diagnostic tests for liver cancer play a crucial role in determining the extent of cancer cell spread within or around the liver following the diagnosis of primary liver carcinoma. A report from the American Cancer Society revealed an increase in new cases of liver and intrahepatic bile duct cancer among females, reaching 13,230 in 2023 in the United States. The total estimated new cases of liver cancer for 2023 in the US are 41,210, with an expected 29,380 fatalities. This underscores the pressing need for liver cancer diagnostics due to the escalating prevalence of the disease.

Key companies in the liver cancer diagnostics market are creating advanced biomarker-based assays and algorithms to enhance diagnostic accuracy and facilitate early detection. Biomarker-based assays and algorithms are diagnostic tools that employ specific biological markers to identify diseases, offering more precise and efficient diagnostic capabilities. For example, in November 2023, Roche Diagnostics, a U.S.-based biotech corporation, introduced the Elecsys PIVKA-II assay and the Elecsys GAAD algorithm. The Elecsys PIVKA-II assay identifies elevated levels of the PIVKA-II biomarker, which is linked to hepatocellular carcinoma (HCC), thereby improving early liver cancer detection in high-risk patients. Meanwhile, the Elecsys GAAD algorithm combines various diagnostic markers, including PIVKA-II and AFP, to enhance diagnostic accuracy and streamline decision-making in liver cancer detection.

In December 2024, Metropolis Healthcare Limited, an India-based healthcare diagnostics company, acquired Core Diagnostics for USD 0.0278 billion. Through this acquisition, Metropolis aims to substantially strengthen its advanced cancer testing capabilities and broaden its footprint across northern and eastern India, reinforcing its position in the specialized diagnostics segment. Core Diagnostics Private Limited is an India-based specialty diagnostics company that offers advanced testing solutions focused on liver cancer diagnostics.

Major companies operating in the liver cancer diagnostics market are Abbott Laboratories, F Hoffmann La Roche Ltd, Qiagen NV, Thermo Fisher Scientific Inc, Siemens Healthineers, Illumina Inc, Koninklijke Philips NV, Epigenomics AG, Digna Biotech SL, Biocept Inc, Danaher Corporation, Foundation Medicine Inc, Agilent Technologies Inc, Genemed Biotechnologies Inc, Merck KGaA, Fujifilm Medical Systems USA Inc, GE Healthcare, Advanced Cell Diagnostics Inc, Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon AS, BioGenex Laboratories Inc, OncoCyte Corporation, Guardant Health Inc, Exact Sciences Corporation, Grail Inc, Freenome Holdings Inc, Natera Inc, Personal Genome Diagnostics Inc, Thrive Earlier Detection Corp

North America was the largest region in the liver cancer diagnostics market in 2025. The regions covered in the liver cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the liver cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The liver cancer diagnostics market includes revenues earned by entities by liver transplants, CT scans, and liver function tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer diagnostics market also includes sales of In Vitro and Imaging Tools, AI tools, and ML tools which are used in providing liver cancer diagnostic services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Liver Cancer Diagnostics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses liver cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liver cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The liver cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type: Hepatocellular Carcinoma; Cholangiocarcinoma; Hepatoblastoma
  • 2) By Screening: Laboratory Testing; Imaging; Biopsy; Other Screenings
  • 3) By Technology: Fluorescent In Situ Hybridization (FISH); Immunohistochemical (IHC); Other Technologies
  • 4) By End Use: Hospitals And Diagnostic Laboratories; Academic And Research Institutes
  • Subsegments:
  • 1) By Hepatocellular Carcinoma: Early-Stage Hepatocellular Carcinoma; Advanced-Stage Hepatocellular Carcinoma
  • 2) By Cholangiocarcinoma: Intrahepatic Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma
  • 3) By Hepatoblastoma: Pure Hepatoblastoma; Mixed Hepatoblastoma
  • Companies Mentioned: Abbott Laboratories; F Hoffmann La Roche Ltd; Qiagen NV; Thermo Fisher Scientific Inc; Siemens Healthineers; Illumina Inc; Koninklijke Philips NV; Epigenomics AG; Digna Biotech SL; Biocept Inc; Danaher Corporation; Foundation Medicine Inc; Agilent Technologies Inc; Genemed Biotechnologies Inc; Merck KGaA; Fujifilm Medical Systems USA Inc; GE Healthcare; Advanced Cell Diagnostics Inc; Oxford Gene Technology; Leica Biosystems Nussloch GmbH; Exiqon AS; BioGenex Laboratories Inc; OncoCyte Corporation; Guardant Health Inc; Exact Sciences Corporation; Grail Inc; Freenome Holdings Inc; Natera Inc; Personal Genome Diagnostics Inc; Thrive Earlier Detection Corp
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Liver Cancer Diagnostics Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Liver Cancer Diagnostics Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Liver Cancer Diagnostics Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Liver Cancer Diagnostics Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Artificial Intelligence & Autonomous Intelligence
    • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.4 Industry 4.0 & Intelligent Manufacturing
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Increasing Adoption Of Advanced Molecular Diagnostic Tests
    • 4.2.2 Rising Use Of Imaging-Based Early Detection Tools
    • 4.2.3 Growing Integration Of Biomarker-Based Screening Methods
    • 4.2.4 Expansion Of Personalized Oncology Diagnostics
    • 4.2.5 Enhanced Focus On Early-Stage Cancer Detection

5. Liver Cancer Diagnostics Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Diagnostic Laboratories
  • 5.3 Academic And Research Institutes
  • 5.4 Pharmaceutical Companies
  • 5.5 Contract Research Organizations

6. Liver Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Liver Cancer Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Liver Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Liver Cancer Diagnostics Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Liver Cancer Diagnostics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Liver Cancer Diagnostics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Liver Cancer Diagnostics Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Liver Cancer Diagnostics Market Segmentation

  • 9.1. Global Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma
  • 9.2. Global Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Laboratory Testing, Imaging, Biopsy, Other Screenings
  • 9.3. Global Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Fluorescent In Situ Hybridization (FISH), Immunohistochemical (IHC), Other Technologies
  • 9.4. Global Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals And Diagnostic Laboratories, Academic And Research Institutes
  • 9.5. Global Liver Cancer Diagnostics Market, Sub-Segmentation Of Hepatocellular Carcinoma, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Early-Stage Hepatocellular Carcinoma, Advanced-Stage Hepatocellular Carcinoma
  • 9.6. Global Liver Cancer Diagnostics Market, Sub-Segmentation Of Cholangiocarcinoma, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma
  • 9.7. Global Liver Cancer Diagnostics Market, Sub-Segmentation Of Hepatoblastoma, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Pure Hepatoblastoma, Mixed Hepatoblastoma

10. Liver Cancer Diagnostics Market Regional And Country Analysis

  • 10.1. Global Liver Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Liver Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Liver Cancer Diagnostics Market

  • 11.1. Asia-Pacific Liver Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Liver Cancer Diagnostics Market

  • 12.1. China Liver Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Liver Cancer Diagnostics Market

  • 13.1. India Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Liver Cancer Diagnostics Market

  • 14.1. Japan Liver Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Liver Cancer Diagnostics Market

  • 15.1. Australia Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Liver Cancer Diagnostics Market

  • 16.1. Indonesia Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Liver Cancer Diagnostics Market

  • 17.1. South Korea Liver Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Liver Cancer Diagnostics Market

  • 18.1. Taiwan Liver Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Liver Cancer Diagnostics Market

  • 19.1. South East Asia Liver Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Liver Cancer Diagnostics Market

  • 20.1. Western Europe Liver Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Liver Cancer Diagnostics Market

  • 21.1. UK Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Liver Cancer Diagnostics Market

  • 22.1. Germany Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Liver Cancer Diagnostics Market

  • 23.1. France Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Liver Cancer Diagnostics Market

  • 24.1. Italy Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Liver Cancer Diagnostics Market

  • 25.1. Spain Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Liver Cancer Diagnostics Market

  • 26.1. Eastern Europe Liver Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Liver Cancer Diagnostics Market

  • 27.1. Russia Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Liver Cancer Diagnostics Market

  • 28.1. North America Liver Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Liver Cancer Diagnostics Market

  • 29.1. USA Liver Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Liver Cancer Diagnostics Market

  • 30.1. Canada Liver Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Liver Cancer Diagnostics Market

  • 31.1. South America Liver Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Liver Cancer Diagnostics Market

  • 32.1. Brazil Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Liver Cancer Diagnostics Market

  • 33.1. Middle East Liver Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Liver Cancer Diagnostics Market

  • 34.1. Africa Liver Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Liver Cancer Diagnostics Market Regulatory and Investment Landscape

36. Liver Cancer Diagnostics Market Competitive Landscape And Company Profiles

  • 36.1. Liver Cancer Diagnostics Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Liver Cancer Diagnostics Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Liver Cancer Diagnostics Market Company Profiles
    • 36.3.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. F Hoffmann La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Qiagen NV Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Thermo Fisher Scientific Inc Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Siemens Healthineers Overview, Products and Services, Strategy and Financial Analysis

37. Liver Cancer Diagnostics Market Other Major And Innovative Companies

  • Illumina Inc, Koninklijke Philips NV, Epigenomics AG, Digna Biotech SL, Biocept Inc, Danaher Corporation, Foundation Medicine Inc, Agilent Technologies Inc, Genemed Biotechnologies Inc, Merck KGaA, Fujifilm Medical Systems USA Inc, GE Healthcare, Advanced Cell Diagnostics Inc, Oxford Gene Technology, Leica Biosystems Nussloch GmbH

38. Global Liver Cancer Diagnostics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Liver Cancer Diagnostics Market

40. Liver Cancer Diagnostics Market High Potential Countries, Segments and Strategies

  • 40.1 Liver Cancer Diagnostics Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Liver Cancer Diagnostics Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Liver Cancer Diagnostics Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer